Table 4.
Univariate and multivariate analysis of overall survival in the patients classified into FIGO 2018 stage IIIC1p.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| (No. of patients) | HR | 95% CI | p value | HR | 95% CI | p value |
| Age (continuous) | 0.995 | 0.983–1.006 | 0.989 | 0.976–1.003 | ||
| Histology | ||||||
| SCC (697) | 1 (reference) | 1 (reference) | ||||
| nSCC (306) | 2.019 | 1.540–2.645 | < 0.001 | 2.157 | 1.560–2.983 | < 0.001 |
| pT classificaion | ||||||
| T1a (1) | NA | NA | NA | NA | NA | NA |
| T1b (474) | 1 (reference) | 1 (reference) | ||||
| T2a (149) | 2.165 | 1.452–3.228 | < 0.001 | 2.158 | 1.355–3.436 | 0.001 |
| T2b (379) | 2.359 | 1.731–3.214 | < 0.001 | 2.367 | 1.594–3.515 | < 0.001 |
| T2a | 1 (reference) | 1 (reference) | ||||
| T2b | 1.089 | 0.756–1.569 | 0.645 | 1.097 | 0.715–1.684 | 0.672 |
| Tumor diameter | ||||||
| ≤ 40 mm (629) | 1 (reference) | 1 (reference) | ||||
| > 40 mm (366) | 1.384 | 1.053–1.819 | 0.020 | 1.034 | 0.750–1.425 | 0.840 |
| LVSI | ||||||
| Negative (130) | 1 (reference) | 1 (reference) | ||||
| Positive (834) | 2.222 | 1.291–3.824 | 0.004 | 1.411 | 0.767–2.596 | 0.268 |
| Stromal invasion | ||||||
| ≤ 1/2 (200) | 1 (reference) | 1 (reference) | ||||
| > 1/2 (701) | 2.065 | 1.346–3.169 | < 0.001 | 1.134 | 0.687–1.874 | 0.622 |
| No. of positive PLN metastasis | ||||||
| Single (424) | 1 (reference) | 1 (reference) | ||||
| Multiple (574) | 2.626 | 1.912–3.607 | < 0.001 | 2.089 | 1.458–2.994 | < 0.001 |
| Ovarian metastasis | ||||||
| Negative/preserved (945) | 1 (reference) | 1 (reference) | ||||
| Positive (18) | 3.663 | 1.937–6.928 | < 0.001 | 2.377 | 1.193–4.735 | 0.014 |
| Corpus invasion | ||||||
| Negative (793) | 1 (reference) | 1 (reference) | ||||
| Positive (192) | 2.022 | 1.506–2.715 | < 0.001 | 1.440 | 1.002–2.069 | 0.049 |
| Adjuvant therapy | ||||||
| CCRT (432) | 1 (reference) | 1 (reference) | ||||
| CT (261) | 1.075 | 0.777–1.487 | 0.664 | 0.940 | 0.643–1.375 | 0.751 |
| RT (242) | 0.831 | 0.580–1.189 | 0.311 | 0.969 | 0.651–1.443 | 0.879 |
| None (31) | 1.407 | 0.652–3.033 | 0.384 | 1.855 | 0.661–5.296 | 0.241 |
| CT | 1 (reference) | 1 (reference) | ||||
| RT | 0.773 | 0.524–1.141 | 0.195 | 1.031 | 0.659–1.612 | 0.894 |
| None | 1.309 | 0.598–2.864 | 0.500 | 1.973 | 0.692–5.619 | 0.203 |
| RT | 1 (reference) | 1 (reference) | ||||
| None | 1.693 | 0.762–3.762 | 0.196 | 1.913 | 0.663–5.518 | 0.230 |
| Peritoneal cytology | ||||||
| Negative (277) | 1 (reference) | |||||
| Positive (41) | 1.914 | 1.092–3.355 | 0.023 | |||
FIGO The International Federation of Gynecology and Obstetrics, HR hazard ratio, CI confidence interval, SCC squamous cell carcinoma, nSCC non-squamous cell carcinoma, PLN pelvic lymph node, LVSI lymphovascular space invasion, CCRT concurrent chemoradiotherapy, CT chemotherapy, RT radiotherapy.